Trasylol News
Bayer Will Begin Pulling Remaining Stock of Trasylol
-Bloomberg.com
05/16/2008- Bayer AG will begin removing the remaining stock of the drug Trasylol, used to control bleeding, from warehouses and hospitals, the U.S. Food and Drug Administration said in a statement today.
Bayer, Germany's largest drugmaker, halted Trasylol sales last year after a study linked the product to a 50 percent higher risk of death than competing drugs in patients undergoing heart surgery.
Trasylol was approved in the U.S. in 1993 to reduce transfusions and bleeding during open-heart surgery. It became a mainstay of care, generating about $333 million in 2005.
Access to Trasylol is limited to certain patients who are at an increased risk of blood loss and transfusions during heart bypass surgery and have no alternative treatments available, the FDA's statement said.
Ennis & Ennis, P.A. is representing individuals that have been harmed as a result of Trasylol side effects. If you or a loved one have suffered as a result of Trasylol side effects such as kidney failure, heart attack, or stroke you may be entitled to compensation. For more information about a Trasylol lawsuit, a possible Trasylol recall, or for questions regarding Trasylol class action lawsuits fill out our free Trasylol case evaluation . Our on-staff nurse and attorneys are standing by to answer any questions you may have regarding Trasylol side effects, a possible Trasylol class action lawsuit, or any other type of Trasylol litigation.
